What Can Recover, What Is Irreversible

Core Concept: Function vs Structure

To understand the reversibility of kidney injury, first distinguish two concepts:

• Functional suppression: Cells and tissues temporarily "stop working," but structure is intact. After removing the suppressing factor, function can recover.
• Structural damage: Cell death, tissue replaced by fibrosis, vessel occlusion. This damage is typically irreversible.

This distinction is crucial for ADPKD patients — it explains why kidney function can improve in some situations but not others.

Reversible: Functional Suppression

Drug-Induced Hemodynamic Changes

ACEI/ARB lower glomerular internal pressure, potentially causing slight eGFR decline at treatment start (usually 10-15%). This is functional suppression — glomerular filtration pressure is reduced, but nephron structure is intact. eGFR rebounds after stopping the drug. This initial decline is not kidney damage — it's a sign the drug is working.

Similarly, NSAIDs constrict afferent arterioles, reversibly lowering GFR. Usually recovers after stopping — but long-term use may cause ischemic damage, becoming irreversible.

Hypovolemia

Dehydration, excessive diuresis, hemorrhage causing hypovolemia reduces renal perfusion and GFR. This is functional suppression — kidney function recovers after fluid replacement. But if severe hypoperfusion persists, it can progress to acute tubular necrosis, becoming structural damage.

Early Stages of Acute Kidney Injury (AKI)

In early AKI, tubular cells may be in a "stunned" state — cells survive but function is suppressed. If the cause is promptly removed (restoring perfusion, stopping nephrotoxins), these cells can recover function. But if injury persists, cells undergo apoptosis or necrosis, becoming irreversible.

Early Cyst Compression

Early cyst compression of surrounding tubules may be functional — tubules are compressed closed but cells survive. If cysts shrink (e.g., tolvaptan reducing cyst volume), some tubular function may recover. This is why tolvaptan better preserves eGFR in early patients — intervening before structural damage occurs.

Hypertension-Induced Glomerular Hypertension

Glomerular hypertension is functional in early stages — controlling blood pressure restores glomerular internal pressure and improves filtration. HALT-PKD confirmed that strict BP control (110/75) better slows TKV growth than standard control (130/80). But long-term hypertension leads to glomerulosclerosis and interstitial fibrosis, becoming irreversible.

Irreversible: Structural Damage

Tubular Atrophy

When cysts chronically compress tubules, or ischemia persists, tubular epithelial cells undergo apoptosis and senescence, tubule diameter shrinks, eventually atrophying and occluding. Atrophied tubules cannot regenerate — this is the core structural damage of ADPKD kidney function loss.

Tubular atrophy is a key marker of CKD progression, predicting eGFR decline better than glomerular pathology. Once it occurs, no current treatment can reverse it.

Interstitial Fibrosis

Ischemia and inflammation activate interstitial fibroblasts, transforming them into myofibroblasts that secrete large amounts of collagen and extracellular matrix, replacing normal renal interstitium. Fibrotic tissue is permanent — no drug can eliminate formed fibrosis (though research is exploring anti-fibrotic treatments).

Fibrosis also causes peritubular capillary rarefaction (capillary loss), worsening ischemia and creating a vicious cycle. Once started, this cycle may self-propagate even if the original cause (cyst growth) is stopped.

Glomerulosclerosis

Long-term hypertension and hyperfiltration cause glomerular capillary loop collapse and mesangial matrix proliferation, forming focal segmental glomerulosclerosis (FSGS). Sclerotic glomeruli permanently lose filtration function. This is why blood pressure control is so important — preventing irreversible glomerular damage.

Atubular Glomeruli

When the tubule connecting to a glomerulus atrophies and occludes, the glomerulus loses its outflow pathway, becoming an "atubular glomerulus" — although the glomerulus itself may appear normal, it effectively loses function because no tubule receives the filtrate. This damage is irreversible.

Aristolochic Acid Nephropathy

Aristolochic acid-induced kidney damage is progressive and irreversible. Aristolochic acid enters proximal tubular cells via organic anion transporters (OAT1/OAT3), forms DNA adducts, causing A→T mutations, apoptosis, and interstitial fibrosis. Even after exposure stops, damage may continue progressing. No effective treatment exists.

This is why avoiding aristolochic acid-containing herbs is so important — prevention is the only protection.

AKI to CKD Transition: Maladaptive Repair

After AKI, some patients progress to chronic kidney disease even after the original cause is removed. The mechanism is maladaptive repair:

1. Dedifferentiation and proliferation: After AKI, surviving epithelial cells dedifferentiate and proliferate to repair tubules.
2. G2/M cell cycle arrest: Some proliferating cells stall at G2/M phase, unable to complete division and redifferentiation.
3. Senescent cell accumulation: G2/M-arrested cells become senescent, secreting pro-fibrotic factors (SASP).
4. Pro-fibrotic microenvironment: Senescent cell factors activate fibroblasts and pericytes, forming myofibroblasts.
5. Capillary rarefaction: Peritubular capillary endothelial cell damage and loss, worsening ischemia.
6. Self-propagating fibrosis: Even after removing the original injury, the fibrotic microenvironment self-maintains, causing progressive fibrosis.

For ADPKD, this means: if AKI occurs (cyst hemorrhage, infection, stone obstruction, contrast nephropathy), it not only acutely damages kidney function but may accelerate long-term CKD progression through maladaptive repair. Therefore preventing AKI is especially important for ADPKD patients.

Why eGFR Decline "Suddenly" Accelerates

ADPKD patients often notice eGFR "suddenly" starts declining rapidly after years of stability. This isn't sudden — it's the result of structural damage accumulating to a critical point:

1. Early: Cysts grow, but normal nephrons compensate, eGFR remains normal.
2. Mid: Cyst compression and ischemia cause some nephron atrophy and fibrosis, but remaining nephrons hyperfiltrate to compensate, eGFR slowly declines.
3. Critical point: When lost nephrons exceed compensatory capacity, eGFR begins to decline noticeably.
4. Late: Fibrosis vicious cycle initiates, eGFR rapidly declines.

This is why TKV growth precedes eGFR decline — structural damage accumulates for years before functional decline. Also why early intervention (before the critical point) is more effective than late intervention.

Tolvaptan's Lesson: Early vs Late Intervention

Tolvaptan clinical trials provide important insights about reversibility:

• TEMPO 3:4 (early patients, eGFR >60): Tolvaptan significantly slowed TKV growth and eGFR decline. Best effect when intervening with less structural damage.
• REPRISE (mid-late patients, eGFR 25-60): Tolvaptan slowed eGFR decline, but less effectively than in early disease. Limited benefit with more structural damage.

This confirms the principle that structural damage is irreversible — tolvaptan can slow future damage but cannot repair existing fibrosis and atrophy. Early identification of rapid progressors and early intervention is key to preserving kidney function.

Limits of Nephron Compensation

When some nephrons are lost, remaining nephrons compensate through hyperfiltration — single-nephron GFR increases to maintain total GFR. But this compensation has costs:

• Hyperfiltration increases glomerular internal pressure and mechanical stress.
• Long-term hyperfiltration leads to glomerulosclerosis and further nephron loss.
• Creates a "nephron loss → hyperfiltration → sclerosis → more loss" vicious cycle.

ACEI/ARB reduce glomerular internal pressure, mitigating hyperfiltration injury and breaking this cycle. This is their core renoprotective mechanism, and why all ADPKD hypertension patients should use ACEI or ARB.

Practical Implications: How You Should Act

Intervene Before Structural Damage

• Regularly monitor TKV and eGFR — understand your disease progression speed.
• Control blood pressure early — prevent glomerulosclerosis and interstitial fibrosis.
• Early tolvaptan for rapid progressors — intervene while structural damage is still reversible.
• Avoid nephrotoxins and AKI — prevent irreversible damage.

When Structural Damage Already Exists

• Don't give up — slowing future damage still has value.
• Strictly control blood pressure and lifestyle factors.
• Discuss with your doctor whether tolvaptan is appropriate (even in late stage, it can slow residual eGFR decline).
• Prepare for renal replacement therapy — understand dialysis and transplant options.

Understanding Test Result Fluctuations

• A single eGFR decline isn't necessarily structural damage — may be functional suppression (dehydration, medications, AKI).
• Focus on long-term trends rather than single values.
• Slight eGFR rebound (e.g., after stopping ACEI) is functional recovery, not structural repair.
• Continued TKV growth with stable eGFR doesn't mean safety — structural damage is accumulating.

Future Hope: Anti-Fibrotic Therapies

No approved anti-fibrotic treatments exist yet, but research is exploring multiple targets:

• Anti-TGF-β therapy (TGF-β is the core fibrosis factor).
• Senolytics — clearing G2/M-arrested senescent cells.
• Pro-regenerative therapy — stimulating tubular epithelial regeneration (currently mainly in animal stages).

These treatments remain in research stages and should not be attempted without medical guidance. But they offer hope for future fibrosis reversal.

← Back to Mechanism